Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Metastatic Triple-Negative Breast Cancer

June 16th 2017

Brain Metastases in HER2-Positive Breast Cancer

June 16th 2017

Triple-Positive Metastatic Breast Cancer

June 16th 2017

Adjuvant Therapy for High-Risk HER2+ Breast Cancer

June 16th 2017

Pending FDA Approval of Neratinib in HER2+ Breast Cancer

June 16th 2017

APHINITY Trial in HER2+ Breast Cancer

June 16th 2017

Extended Adjuvant Therapy for HER2-Positive Breast Cancer

June 16th 2017

Adjuvant Therapy for HER2-Driven Breast Cancer

June 16th 2017

PI3K Inhibitors for HR+ Metastatic Breast Cancer

June 16th 2017

Sequencing in Hormone-Driven Metastatic Breast Cancer

June 16th 2017

Endocrine Resistance in HR+ Metastatic Breast Cancer

June 16th 2017

Emerging CDK4/6-Targeted Therapy for Breast Cancer

June 16th 2017

Choosing Therapy for HR+ Metastatic Breast Cancer

June 16th 2017

CDK4/6 Inhibitors for HR+ Metastatic Breast Cancer

June 16th 2017

FDA Approval of Ribociclib for Metastatic Breast Cancer

June 16th 2017

Dr. Freedman Discusses CNS Metastases in HER2+ Breast Cancer

June 15th 2017

Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses brain metastases in patients with HER2-positive breast cancer.

Dr. Houber on the De-Escalation of Treatments for Breast Cancer

June 6th 2017

Jens Huober, MD, professor of gynecologic oncology, Ulm University Hospital, discusses the de-escalation of treatments for patients with breast cancer.

Dr. von Minckwitz on Phase III Results of the APHINITY Trial for Breast Cancer

June 6th 2017

Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses the phase III results of the APHINITY trial, which explored the addition of pertuzumab (Perjeta) to standard postoperative trastuzumab (Herceptin) therapy for patients with HER2-positive early breast cancer.

Dr. Hayes on the Future of Biomarkers for Breast Cancer

June 6th 2017

Daniel F. Hayes, MD, professor at the University of Michigan Comprehensive Cancer Center, discusses the future of biomarkers for patients with breast cancer.

Adjuvant Pertuzumab May Help Some Early Breast Cancer Patients

June 5th 2017

The addition of pertuzumab (Perjeta) to standard postoperative trastuzumab (Herceptin) therapy for patients with HER2-positive early breast cancer slightly improved the rate of recurrence overall but had a greater benefit for individuals with higher-risk disease, particularly as more time elapsed, according to early results from the phase III APHINITY trial.